Metoclopramide is used for the symptomatic treatment of post-operative or chemotherapy-induced nausea and vomiting, gastroesophageal reflux disease and gastroparesis. Metoclopramide is generally ...

Nov. 07, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on ...

Get detailed information on Metoclopramide, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated ...

Metoclopramide use during early pregnancy was not associated with excess risk for congenital malformations. In the U.S., treatment of nausea and vomiting during early pregnancy usually involves ...

Evoke Pharma (EVOK) shares rocketed 90% on positive data for its nasal drug Gimoti in the treatment of stomach paralysis in ...

Metoclopramide is a central dopamine D2-receptor antagonist used as an antiemetic and gastroprokinetic agent in dogs and cats 1,2,3,4. It has been used experimentally in pigeons as an antiemetic ...

Approved to treat diabetic gastroparesis, Gimoti is co-marketed with Eversana. Evoke underlined that nasal delivery provides ...

Report on how AI is redefining market landscape - The global gastroparesis drugs market  size is estimated to grow by USD 1.42 billion from 2024-2028, according to Technavio. The market is estimated ...

Evoke Pharma Inc (NASDAQ: EVOK) opened well over 100% up on Monday after reporting positive results for a study on its ...

Evoke Pharma shares rose 70% on Monday after presenting data on Gimoti in GLP-1 users. Shares were trading around $9 in recent trading. The stock is down more than 28% on the year so far.

The study compared healthcare resource utilization of patients using Gimoti, a nasal formulation of the drug metoclopramide, versus oral metoclopramide, specifically focusing on individuals who ...

The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of ...